Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

The MYC Oncogene Initiates and Maintains Metastasis in Mouse Prostate Cancer Model

By BiotechDaily International staff writers
Posted on 12 Feb 2014
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
A mouse metastatic prostate cancer model is expected to enable researchers to better investigate the causes of the disease while at the same time test new therapeutics to treat it.

The RapidCaP genetically engineered mouse (GEM) system was developed by investigators at Cold Spring Harbor Laboratory (NY, USA) who injected viral genes directly into mouse prostate tumors in order to induce them to metastasize.

Examination of these animals and analysis at the molecular level revealed that PI 3-kinase activity, a well-known modulator of prostate cancer, was absent from the RapidCaP metastasized tumors, and that the MYC oncogene was acting as the driving force behind the spread of the tumor. Indeed, they found that prostate tumors could be driven to metastasize simply by increasing the amount of Myc protein.

MYC (v-myc myelocytomatosis viral oncogene homolog protein) is a transcription factor that activates expression of a great number of genes through binding on consensus sequences and recruiting histone acetyltransferases (HATs). By acting as a transcriptional repressor in normal cells, MYC has a direct role in the control of DNA replication. The MYC protein (c-Myc) is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.

The investigators used RapidCaP to show that Myc both triggered local prostate metastasis and was critical for its maintenance. They further reported in the January 20, 2014, online edition of the journal Cancer Discovery that by treating these animals with the drug JQ1, which reduces the amount of Myc in cells, they could shrink the metastases, suggesting that the switch to Myc was required for maintenance of tumor cells that have metastasized throughout the body.

“The RapidCaP system has revealed a specific role for Myc as a druggable driver of metastasis in prostate cancer,” said senior author Dr. Lloyd Trotman. “So there is hope that our model provides a fast and faithful test-bed for developing new approaches to cure the type of prostate cancer that today is incurable.”

Related Links:

Cold Spring Harbor Laboratory



Channels

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel
Image: Induced pluripotent stem (iPS) cells, which act very much like embryonic stem cells, are shown growing into heart cells (blue) and nerve cells (green) (Photo courtesy of Gladstone Institutes/Chris Goodfellow).

Methodology Devised to Improve Stem Cell Reprogramming

In a study that provides scientists with a critical new determination of stem cell development and its role in disease, researchers have established a first-of-its-kind approach that outlines the stages... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.